Effects of Cyclophosphamide on Lung Function in Scleroderma Patients
Author Information
Author(s): Nannini Carlotta, West Colin P, Erwin Patricia J, Matteson Eric L
Primary Institution: Mayo Clinic College of Medicine
Hypothesis
Does cyclophosphamide treatment improve pulmonary function in patients with systemic sclerosis and interstitial lung disease?
Conclusion
Cyclophosphamide treatment does not result in clinically significant improvement of pulmonary function in patients with systemic sclerosis-related interstitial lung disease.
Supporting Evidence
- Cyclophosphamide treatment did not achieve a clinically meaningful improvement in lung function.
- The mean change in forced vital capacity was 2.83%, which is not statistically significant.
- The mean change in diffusing capacity for carbon monoxide was 4.56%, also not statistically significant.
Takeaway
Cyclophosphamide is a medicine that some people thought might help with lung problems in scleroderma, but it doesn't really make a big difference.
Methodology
A systematic review and meta-analysis of randomized controlled trials and observational studies assessing the effects of cyclophosphamide on lung function.
Potential Biases
Potential biases due to the variability in study quality and treatment protocols.
Limitations
The studies included varied in patient demographics, treatment regimens, and follow-up duration, which may affect the results.
Participant Demographics
Patients with systemic sclerosis and interstitial lung disease, including both limited and diffuse forms.
Statistical Information
Confidence Interval
FVC: 95% CI = 0.35 to 5.31; DLCO: 95% CI = -0.21 to 9.33
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website